Getagraph.com logo
S&P 500 Futures
(0.44%) 5 068.75 points
Dow Jones Futures
(0.31%) 38 186 points
Nasdaq Futures
(0.55%) 17 534 points
Oil
(0.58%) $79.46
Gas
(1.55%) $1.962
Gold
(0.49%) $2 322.30
Silver
(0.08%) $26.77
Platinum
(1.32%) $967.50
USD/EUR
(0.03%) $0.933
USD/NOK
(0.13%) $11.04
USD/GBP
(-0.02%) $0.798
USD/RUB
(-1.09%) $92.25

Realaus laiko atnaujinimai Protalix Biotherapeutics [PLX]

Birža: AMEX Sektorius: Healthcare Pramonė: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-02)

Expected move: +/- 0.00%

Atnaujinta1 geg. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

6.14% $ 1.210

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally...

Stats
Šios dienos apimtis 355 268
Vidutinė apimtis 373 129
Rinkos kapitalizacija 88.39M
EPS $0 ( 2024-03-14 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 13.44
ATR14 $0.00400 (0.33%)
Insider Trading
Date Person Action Amount type
2024-04-01 Bashan Dror Buy 263 960 Common Stock
2023-10-19 Bashan Dror Buy 16 129 Common Stock
2023-10-19 Bashan Dror Buy 48 387 Common Stock
2023-09-29 Boudes Pol F Buy 61 676 Stock Options (Right to Buy)
2023-09-29 Melincoff Gwen A Buy 61 676 Stock Options (Right to Buy)
INSIDER POWER
100.00
Last 87 transactions
Buy: 22 496 164 | Sell: 34 117 800

Tūris Koreliacija

Ilgas: 0.06 (neutral)
Trumpas: -0.93 (very strong negative)
Signal:(26.004) Possible Trading Opportunity Present (swing)

Protalix Biotherapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Protalix Biotherapeutics Koreliacija - Valiuta/Žaliavos

The country flag 0.87
( strong )
The country flag 0.91
( very strong )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.93
( very strong negative )

Protalix Biotherapeutics Finansinės ataskaitos

Annual 2023
Pajamos: $65.49M
Bruto pelnas: $42.51M (64.91 %)
EPS: $0.120
FY 2023
Pajamos: $65.49M
Bruto pelnas: $42.51M (64.91 %)
EPS: $0.120
FY 2022
Pajamos: $47.64M
Bruto pelnas: $28.05M (58.87 %)
EPS: $-0.310
FY 2021
Pajamos: $38.35M
Bruto pelnas: $22.00M (57.37 %)
EPS: $-0.620

Financial Reports:

No articles found.

Protalix Biotherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.